SCHEMBL3265517

SCHEMBL3265517

CCCCNCc1cc(C)ccn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.44
KDM1A O60341 1/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
KDM4E B2RXH2 3/20 0.41
SCN8A Q9UQD0 1/20 0.41
HPGD P15428 1/20 0.41
UTS2R Q9UKP6 1/20 0.41
SIRT2 Q8IXJ6 4/20 0.40
HRH4 Q9H3N8 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
UHRF1 Q96T88 1/20 0.38
CCR1 P32246 1/20 0.38
CCR5 P51681 1/20 0.38
CCR8 P51685 1/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
HTR1A P08908 4/20 0.38
ADRA1D P25100 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10483857 0.85 CHRM2 (0.42) CHRM2KDM1AMAOAMAOBKDM4E
SCHEMBL10483874 0.85 KDM1A (0.43) CHRM2KDM1AMAOAMAOBKDM4E
SCHEMBL23428545 0.84 CHRM2 (0.45) CHRM2KDM1AMAOAMAOBKDM4E
SCHEMBL2259096 0.82 KDM1A (0.47) KDM1AMAOAMAOBKDM4EHPGD
SCHEMBL16293037 0.82 CHRM2 (0.44) CHRM2KDM1AMAOAMAOBKDM4E
SCHEMBL19582240 0.79 TERT (0.43) KDM1AMAOAMAOBSIRT2HRH3
SCHEMBL645891 0.77 NOS2 (0.50) KDM4EHPGDUTS2RUHRF1CCR1
SCHEMBL29779666 0.77 NOS2 (0.50) KDM4EHPGDUTS2RUHRF1CCR1
SCHEMBL20170980 0.77 HTR1A (0.41) KDM1AMAOAMAOBKDM4EHPGD
SCHEMBL21637975 0.76 MC5R (0.55) CHRM2KDM1AMAOAMAOBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004262-A1 PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE ORYZON GENOMICS, S.A. (ES) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004262-A1 PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE PNMT, ABCB1, SNCA CHRM2 201/4885KDM1A 1515/4885MAOA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.